Nostopharma, LLC
Repurposed small molecule combination therapies targeting Hedgehog pathway inhibition for rare genetic diseases
- Sector
- Biotech
- Headquarters
- Potomac, MD
- Latest Form D
- $250K, Sep 2024
- Total capital
- $2.1M
- Federal grants
- $1.6M
- 4 awards · 2022–2024
- Rank in peer group#72 of 326
- Private capital raised
- $500K
- 2 Form D · last Sep 2024
- 25 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 5 pending · first 2019
- Rank in peer group#58 of 326
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$250K
- Federal grantNSF · Phase II · SBIR Phase II: Improved drug delivery platforms for localized and sustained drug deposition for traumatic injuries$1M
- Federal grantHealth and Human S · Phase I · Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease$44K
- Federal grantHealth and Human S · Phase I · Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease$319K
- Private capital raisedForm D · SEC · 1st filing$250K
- Federal grantNSF · Phase I · STTR Phase I:Improved drug delivery platforms for localized and sustained drug deposition for traumatic injuries$256K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
16months
from Nostopharma, LLC’s first federal award to its first private round.
- First federal award · Mar 2022
- NSF · $256K
- First Form D · Jun 2023
- $250K · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#72 · top 22%
- Granted patents#58 · top 18%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Ekaterina Vert-WongResearcherExecutive Officer, DirectorLinked by 2 patents · $1M in grants as PI
- Jelena JeremicResearcherExecutive Officer, DirectorLinked by $575K in grants as PI
- Jelena Gvozdenovic-JeremicExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 7- PendingLocalized Delivery Of Therapeutic AgentsUSPTOApplication 17438195
- GrantedCompositions and Methods for Preventing and Treating Heterotopic Ossification and Pathologic CalcificationUSPTOUS 10,548,908
- GrantedCompositions and Methods for Preventing and Treating Heterotopic Ossification and Pathologic CalcificationUSPTOUS 10,456,409
Show all 7 patent records
- Localized Delivery Of Therapeutic AgentsApr 28, 2022 · Application 17438195Pending
- Compositions and Methods for Preventing and Treating Heterotopic Ossification and Pathologic CalcificationFeb 4, 2020 · US 10,548,908Granted
- Compositions and Methods for Preventing and Treating Heterotopic Ossification and Pathologic CalcificationOct 29, 2019 · US 10,456,409Granted
- Compositions And Methods For Preventing And Treating Heterotopic Ossification And Pathologic CalcificationApplication PCTUS2018021776Pending
- Localized Delivery of Hedgehog Signaling Pathway Antagonists, Statins and Vitamin DApplication 62817531Pending
- Localized Delivery Of Therapeutic AgentsApplication PCTUS2020021900Pending
- Localized Delivery of Therapeutic AgentsApplication 62939439Pending
Related companies, and why
- Cardurion PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- ABSCO THERAPEUTICS, INC. D/B/A ABSCOTXSimilar federal contract value in Biotech · null in contracts
- Stipple BioSimilar federal contract value in Biotech · null in contracts
- PROLYNX, LLCSimilar federal contract value in Biotech · null in contracts
- SQZ Biotechnologies CompanySimilar federal contract value in Biotech · null in contracts
- KSQ TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .